Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
Richard S. Finn,Shukui Qin,Masafumi Ikeda,Peter R. Galle,Michel Ducreux,Tae-You Kim,Masatoshi Kudo,Valeriy Breder,Philippe Merle,Ahmed O Kaseb,Daneng Li,Wendy Verret,Derek-Zhen Xu,Sairy Hernandez,Juan Liu,Chen Huang,Sohail M. Mulla,Yulei Wang,Ho Yeong Lim,Andrew X. Zhu,Ann-Lii Cheng,IMbrave Investigators +21 more
TLDR
In patients with unresectable hepatocellular carcinoma, atezolIZumab combined with bevacizumab resulted in better overall and progression-free survival outcomes than sorafenib.Abstract:
Background The combination of atezolizumab and bevacizumab showed encouraging antitumor activity and safety in a phase 1b trial involving patients with unresectable hepatocellular carcinom...read more
Citations
More filters
Journal ArticleDOI
Cancer statistics, 2023
TL;DR: The American Cancer Society estimates the number of new cancer cases and deaths in the United States and compiles the most recent data on population-based cancer occurrence and outcomes using incidence data collected by central cancer registries and mortality data collected from the National Center for Health Statistics as discussed by the authors .
Journal ArticleDOI
BCLC strategy for prognosis prediction and treatment recommendation Barcelona Clinic Liver Cancer (BCLC) staging system. The 2022 update.
M. Reig,Alejandro Forner,Jordi Rimola,Joana Ferrer-Fàbrega,Marta Burrel,Ángeles García-Criado,Robin Katie Kelley,Peter R. Galle,Vincenzo Mazzaferro,Riad Salem,Bruno Sangro,Amit G. Singal,Arndt Vogel,Josep Fuster,C. Ayuso,Jordi Bruix +15 more
TL;DR: In this paper, the authors present those that have primed a change in the strategy and comment why some encouraging data in select interventions are still considered immature and in need to further research to gain their incorporation into an evidence-based model for clinicians and researchers.
Journal ArticleDOI
BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update
TL;DR: Forner et al. as mentioned in this paper discussed the critical insight and expert knowledge that are required to make clinical decisions for individual patients, considering all of the parameters that must be considered to deliver personalised clinical management.
Journal ArticleDOI
Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma
Richard S. Finn,Masafumi Ikeda,Andrew X. Zhu,Max W. Sung,Ari David Baron,Masatoshi Kudo,Takuji Okusaka,Masahiro Kobayashi,Hiromitsu Kumada,Shuichi Kaneko,Marc Pracht,Konstantin Mamontov,Tim Meyer,Tomoki Kubota,Corina E. Dutcus,Kenichi Saito,Abby B. Siegel,Leonid Dubrovsky,Kalgi Mody,Josep M. Llovet,Josep M. Llovet +20 more
TL;DR: Lenvatinib plus pembrolizumab has promising antitumor activity in uHCC, and toxicities were manageable, with no unexpected safety signals.
Journal ArticleDOI
NASH limits anti-tumour surveillance in immunotherapy-treated HCC
Dominik Pfister,Dominik Pfister,Nicolás Gonzalo Núñez,Roser Pinyol,Olivier Govaere,Matthias Pinter,Marta Szydlowska,Revant Gupta,Mengjie Qiu,Aleksandra Deczkowska,Assaf Weiner,Florian Müller,Ankit Sinha,Ankit Sinha,Ekaterina Friebel,Thomas Engleitner,Thomas Engleitner,Daniela Lenggenhager,Anja Moncsek,Danijela Heide,Kristin Stirm,Jan Kosla,Eleni Kotsiliti,Valentina Leone,Michael Dudek,Suhail Yousuf,Donato Inverso,Donato Inverso,Indrabahadur Singh,Ana Teijeiro,Florian Castet,Carla Montironi,Philipp K. Haber,Dina Tiniakos,Dina Tiniakos,Pierre Bedossa,Simon Cockell,Ramy Younes,Ramy Younes,Michele Vacca,Fabio Marra,Jörn M. Schattenberg,Michael Allison,Elisabetta Bugianesi,Vlad Ratziu,Tiziana Pressiani,Antonio D'Alessio,Nicola Personeni,Lorenza Rimassa,Ann K. Daly,Bernhard Scheiner,Katharina Pomej,Martha M. Kirstein,Arndt Vogel,Markus Peck-Radosavljevic,F. Hucke,Fabian Finkelmeier,Oliver Waidmann,Jörg Trojan,Kornelius Schulze,Henning Wege,Sandra Koch,Arndt Weinmann,Marco Bueter,Fabian Rössler,Alexander Siebenhüner,Sara De Dosso,Jan-Philipp Mallm,Viktor Umansky,Viktor Umansky,Manfred Jugold,Tom Luedde,Andrea Schietinger,Andrea Schietinger,Peter Schirmacher,Brinda Emu,Hellmut G. Augustin,Hellmut G. Augustin,Adrian T. Billeter,Beat P. Müller-Stich,Hiroto Kikuchi,Dan G. Duda,Fabian Kütting,Dirk Waldschmidt,Matthias P. Ebert,Nuh N. Rahbari,Henrik E. Mei,Axel Schulz,Marc Ringelhan,Nisar P. Malek,Stephan Spahn,Michael Bitzer,Marina Ruiz de Galarreta,Amaia Lujambio,Jean-François Dufour,Thomas U. Marron,Thomas U. Marron,Ahmed Kaseb,Masatoshi Kudo,Yi Hsiang Huang,Yi Hsiang Huang,Nabil Djouder,Katharina Wolter,Lars Zender,Lars Zender,Parice N. Marche,Parice N. Marche,Thomas Decaens,Thomas Decaens,David J. Pinato,Roland Rad,Roland Rad,Joachim C. Mertens,Achim Weber,Kristian Unger,Felix Meissner,Susanne Roth,Zuzana Macek Jilkova,Zuzana Macek Jilkova,Zuzana Macek Jilkova,Manfred Claassen,Quentin M. Anstee,Ido Amit,Percy A. Knolle,Burkhard Becher,Josep M. Llovet,Josep M. Llovet,Josep M. Llovet,Mathias Heikenwalder +128 more
TL;DR: The progressive accumulation of exhausted, unconventionally activated CD8+PD1+ T cells in NASH-affected livers provides a rationale for stratification of patients with HCC according to underlying aetiology in studies of immunotherapy as a primary or adjuvant treatment.
References
More filters
Journal ArticleDOI
Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases
Jorge A. Marrero,Laura Kulik,Claude B. Sirlin,Andrew X. Zhu,Richard S. Finn,Michael Abecassis,Lewis R. Roberts,Julie K. Heimbach +7 more
TL;DR: This paper aims to demonstrate the efforts towards in-situ applicability of EMMARM, as to provide real-time information about concrete mechanical properties such as E-modulus and compressive strength.
Journal ArticleDOI
Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy.
TL;DR: A humanized anti-VEGF monoclonal antibody has been approved by the FDA as a first-line treatment for metastatic colorectal cancer in combination with chemotherapy and VEGF is implicated in intraocular neovascularization associated with diabetic retinopathy and age-related macular degeneration.
Journal ArticleDOI
A graphical approach to sequentially rejective multiple test procedures
TL;DR: A simple iterative graphical approach to construct and perform Bonferroni-type tests, represented by directed, weighted graphs, where each node corresponds to an elementary hypothesis, together with a simple algorithm to generate such graphs while sequentially testing the individual hypotheses.
Related Papers (5)
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
Masatoshi Kudo,Richard S. Finn,Shukui Qin,Kwang Hyub Han,Kenji Ikeda,Fabio Piscaglia,Ari David Baron,Joong-Won Park,Guohong Han,Jacek Jassem,Jean-Frédéric Blanc,Arndt Vogel,Dmitry Komov,T.R. Jeffry Evans,Carlos Lopez,Corina E. Dutcus,Matthew Guo,Kenichi Saito,Silvija Kraljevic,Toshiyuki Tamai,Min Ren,Ann-Lii Cheng +21 more
Sorafenib in Advanced Hepatocellular Carcinoma
Josep M. Llovet,Sergio Ricci,Vincenzo Mazzaferro,Philip Hilgard,Edward Gane,Jean-Frédéric Blanc,André Cosme de Oliveira,Armando Santoro,Jean-Luc Raoul,Alejandro Forner,Myron Schwartz,Camillo Porta,Stefan Zeuzem,Luigi Bolondi,Tim F. Greten,Peter R. Galle,Jean Francois Seitz,Ivan Borbath,Dieter Häussinger,Tom Giannaris,Minghua Shan,M. Moscovici,D. Voliotis,Jordi Bruix +23 more
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
Jordi Bruix,Shukui Qin,Philippe Merle,Alessandro Granito,Yi Hsiang Huang,György Bodoky,Marc Pracht,Osamu Yokosuka,Olivier Rosmorduc,Valeriy Breder,René Gerolami,Gianluca Masi,Paul Ross,Tianqiang Song,Jean-Pierre Bronowicki,Isabelle Ollivier-Hourmand,Masatoshi Kudo,Ann-Lii Cheng,Josep M. Llovet,Josep M. Llovet,Josep M. Llovet,Richard S. Finn,Marie Aude Leberre,Annette Baumhauer,Gerold Meinhardt,Guohong Han +25 more